Skip to main content
. 2015 May 28;21(20):6352–6360. doi: 10.3748/wjg.v21.i20.6352

Table 3.

Summary of most common adverse events (occurring in 10% or more of patients in any group)

Ref. Group General adverse events1
Ulcerative colitis aggravated Nausea/vomiting Headache Frequent bowel movements Fatigue Upper respiratory tract infection Abdominal pain/tenderness Arthralgia Dizziness Rash
Feagan et al[14] Intervention 1 29 (50) 21 (36) 12 (21) 10 (17) 8 (14) 8 (14) 10 (17) 4 (7) 6 (10) 6 (10)
Intervention 2 22 (37) 13 (22) 11 (18) 5 (8) 5 (8) 8 (13) 6 (10) 7 (12) 4 (7) 4 (7)
Control 24 (38) 15 (24) 13 (21) 10 (16) 7 (11) 5 (8) 16 (25) 5 (8) 1 (2) 4 (6)
Feagan et al[15] Intervention 97 (13) 38 (5) 80 (11) NA 33 (4) 132 (18) 50 (7) 56 (8) NA NA
Control 58 (39) 19 (13) 28 (19) NA 10 (7) 47 (32) 10 (7) 25 (17) NA NA
Parikh et al[16] Intervention 1 2 (17) NA 2 (17) NA NA 4 (33) NA NA 1 (8) NA
Intervention 2 1 (7) NA 3 (21) NA NA 3 (21) NA NA 0 (0) NA
Intervention 3 0 (0) NA 2 (18) NA NA 1 (9) NA NA 0 (0) NA
Control 4 (44) NA 1 (11) NA NA 4 (44) NA NA 1 (11) NA
Feagan et al[14] Intervention 1 6 (10) NA NA NA NA NA NA 6 (10) 18 (15)2
Intervention 2 3 (5) NA NA NA NA NA NA 12 (20)
Control 8 (13) NA NA NA NA NA NA 6 (10)
Feagan et al[15] Intervention NA 35 (5) 13 (2) NA NA NA NA 77 (10)
Control NA 16 (11) 36 (24) NA NA NA NA 37 (25)
Parikh et al[16] Intervention 1 NA NA 0 (0) 0 (0) 0 (0) 1 (8) 0 (0) 1 (8) 2 (5)2
Intervention 2 NA NA 2 (14) 2 (14) 2 (14) 0 (0) 0 (0) 0 (0)
Intervention 3 NA NA 0 (0) 0 (0) 0 (0) 0 (0) 1 (9) 1 (9)
Control NA NA 0 (0) 0 (0) 0 (0) 1 (11) 1 (11) 0 (0)
1

Data reported as n (%);

2

Pooled of all intervention groups. NA: Not available.